Ladies and gentlemen, welcome to the Arrowhead Pharmaceutical's Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Thanks, Liz. Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its fiscal 2017 fourth quarter and year ended September 30, 2017. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Bruce Given, our Chief Operating Officer and Head of R&D, who will discuss our near term clinical candidates and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. We will then open up the call to your questions. Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, including without limitation, those with respect to Arrowhead's goals, plans and strategies, are forward-looking statements. These include statements regarding our expectations around the development, safety and efficacy of our drug candidates, projected cash runway and expected future development activities. These statements represent management's current expectations and are inherently uncertain. Thus, actual results may differ materially. Arrowhead disclaims any intent and undertakes no duty to update any of the forward-looking statements discussed on today's call. You should refer to the discussions under risk factors in Arrowhead's annual report on Form 10-K and the Company's subsequent quarterly reports on Form 10-Q for additional matters to be considered in this regard including risks and other considerations that could cause actual results to vary from the presently expected results expressed in today's call. With that said, I’d like to turn the call over to Dr. Christopher Anzalone, President and CEO of the company. Chris?

Thanks, Vince. Good afternoon everyone, and thank you for joining us today. 2017 has been an enormously productive year for Arrowhead, as we moved forward from a very difficult position in 2016 to discontinue development of prior generation drugs, ARC-520, ARC-521, and ARC-AAT to utilize the EX1 delivery vehicle. That decision moved from a clinical stage company with two Phase 2 candidates and a one Phase 1 candidate to a preclinical stage company overnight. In addition, at that time we had not disclosed much about our new platform and not given guidance on timelines for getting back into the clinic. Understandably, there was a lot of uncertainty for investors about where Arrowhead was going. We are clearly on our heels but the real medal of a company only makes itself known in the face of adversity. As we look back on what we accomplished and forward to what is to come I am extraordinarily proud of this company. We are on pace to file two CTAs to begin clinical trials during the next two quarters. These are for ARO-AAT to treat alpha-1 liver disease with the CTA planned in Q1, 2018 and ARO-HBV as a potentially cured of therapy for chronic hepatitis B virus infection with a CTA planned in Q2 2018. We think the insights going from our prior programs in HPV and alpha-1 liver disease represent real competitive and strategic advantages and should enable us to move with speed and precision once the clinical programs begin. We are also on schedule to file three additional CTAs in the next 12 months. These are for ARO-APOC3, and ARO-ANG3, to treat hypertriglyceridemia and ARO-Lung1 against an undisclosed lung disease target; all three are planned for CTA filings around the end of 2018. In addition, our two cardiovascular collaborations with Amgen…

Thank you, Chris and good afternoon everyone. Chris mentioned that ARO-AAT and ARO-HBV are on pace for CTA filings during the first two quarters, and then we anticipate having up to three additional CTAs before the end of 2018. These were all very exciting programs for us. Today I want to focus just on ARO- AAT and ARO-HBV since they are our current lead programs and are on pace to get into the clinic shortly. I will go over two areas for each candidate. The therapeutic rationale for the target and select data that provides us with confidence in the candidate’s potential. Let’s start with ARO-AAT. The alpha-1 antitrypsin or AAT deficiency involves a genetic mutation that causes the AAT protein to be misfolded and does not properly export from hepatocytes. This causes two downstream issues for patients with this disorder; first, AAT protects tissues from inflammation and damage, patient that have the misfolded protein have low circulating levels of AAT which can lead to early-onset lung disease. Second, since the protein is not properly exported from the liver, it accumulates and then aggregates into polymers and globules inside the cell. So the lung disease is due to deficiency and functional AAT, but in the liver, it’s a storage disease. There are approved protein replacement therapies for the lung disease, but at this time the only option for treating the liver disease is transplant. There are estimated to be around 100,000 potential patients in the U.S. and possibly more in Europe with alpha-1 antitrypsin deficiency. Based on those numbers, it qualifies for orphan disease designation, but it is one of the more common rare diseases. RNAi is a mechanism, it’s very good at halting the production of an individual protein, so we think alpha-1 liver disease which is clearly caused…

Thank you Bruce and good afternoon everyone. As we reported today our net loss for the fiscal 2017 was $34.4 million or $0.47 per share based on 73.9 million weighted average shares outstanding. This compares with a net loss of $81.7 million or $1.34 per share based on a 61.1 million weighted shares outstanding for the fiscal 2016. Revenue for fiscal 2017 was $31.4 million compared to $158,000 for fiscal 2016. The increase is driven by the upfront payments received from our collaboration agreements with Amgen. During fiscal 2017, we have recognized revenue for albeit $5.3 million related to the Amgen agreements and we expect to recognize the balance in fiscal 2018. Total operating expenses for the year ended September 30, 2017 were $68.4 million compared to $81.9 million for the year ended September 30, 2016. Net cash used in operating activities in fiscal 2017 was $23.9 million compared with $64.4 million for fiscal 2016. Our R&D expenses declined from $41.5 million to $31.7 million primarily due to discontinuation of our previous clinical candidates in November of last year, although closed down expenses continued into the fiscal second quarter; Salary and payroll expense also declined due to the workforce reduction we put in place after the discontinuation of our previous clinical candidates. General and administrative expenses also declined primarily due to a reduced professional services expenses. Turning to our balance sheet our cash and short term investments totalled $65.6 million as of September 30, 2017 compared to our cash balance of $85.4 million at September 30, 2016. The decrease in our cash and investments balance reflects cash used in operations of $53.9 million and $7.8 million of capital expenditures primarily related to the build out of our new research facility in Madison. Offset by $42.5 million in cash received from Amgen consisting of $30 million upfront payment for ARO-LPA and $12.5 million in additional equity investment. Our common shares at September 30, 2017 was 74.8 million. With that brief overview, I'll turn the call back to Chris.

Thanks, Ken. As you can see we’ve had an incredible amount of progress throughout 2017 and we believe that 2018 is set up to be transformational. Transition onto the TRiM platform has been rapid and we expect to file CTAs for five drug candidates in calendar 2018 where we believe we have strong competitive advantages. We are clear leaders in alpha-1 liver disease and expect to be the only company with the clinical candidate against this manifestation of alpha-1 antitrypsin deficiency in the first quarter of 2018. We are clear intellectual leaders in chronic HBV expect to be once again development leaders in RNAi treatment of HBV. We believe that RNAi will become a backbone therapy for HBV and we plan on being back in the clinic in the second quarter with what we see as the first RNAi therapeutic with a real chance of enabling functional cures. We are leaders in RNAi for cardiovascular disease and believe that Amgen with a candidate we developed will be the first company to use RNAi against LP(a) in humans. Similarly, we expect to file CTAs for ARO-ANG3, and ARO-APOC3 by the end of 2018 and that we will be the first company to use RNAi against Angiopoietin-3 and apolipoprotein C-III in humans. We are also now leaders in RNAi for lung targets. This opens a new chapter for us and enables us to go after diseases in ways no other company is capable of – at present. We expect to file a CTA for our first lung candidate by the end of 2018 and believe we will be the only company with a viable approach to using RNAi against the lung diseases with inhaled administration. This is certainly a lot but given our non-clinical data and experience in AAT and HBV, we feel comfortable with these aggressive plans. It is also safe to assume that we will continue to build our pipeline in 2018 and that we will go after additional high value disease targets where new therapies are badly needed by patients. Our ability to create new potential medicines outstrips our ability to develop them all into marketed products at least for now. Therefore it makes sense to do more collaborations like we did with Amgen last year for some of our programs. The world has seen how fast we were able to move over the past 12 months, and that the TRiM technology may be optimized to address a variety of target tissues, so we believe we are well positioned to attract high quality partners to maximize the number of products we can ultimately get to patients. It has been a very productive 2017 and we look forward to an exciting 2018. I would now like to open the call up for your questions. Operator?

Thank you. [Operator Instructions] Our first question comes from the line of Katherine Xu with William Blair. Your line is now open.

Hello?

Hi, Katherine.

Hi, hi good afternoon. Thank you for the call. I have a few questions. First, I was just wondering given the very interesting data that you saw with the ARC-520, do you think we would need to – in the future you would need to stop treatment to gather any response or you just keep treating until you try everything down at year end, and then removal [Indiscernible] do you think that during the treatment period you will see that respond? And my second question is, what is the timing of the proof of concepts for ARO-AAT and ARO-HBV? Are we going to see the proof of concept data in 2018? And lastly, on the safety side, apparently this is most important for the new platform. Can you comment on any incremental information you can provide, I understand that there was very good therapeutic – and large safety margin in the GLP tox studies? Any incremental information on the [Indiscernible] talks and other safety aspects? Thank you.

Okay, so help me, let me know if I forget any of the three here. So with respect to the first question about needing to stop treatment with ARO-HBV to see a sustained host response the answer is we don’t know. That’s a good question. That was certainly not the intention for ARC-520. We had to discontinue that program and so we are able to follow ample of patients after that. But we’ll just have to see, you know we think that ARO-HBV is going to be – is going to be a powerful drug here because it’s going to – it’s designed to knock down s-antigen coming out for both cccDNA as well as integrated DNA, so it’s got a shot of knocking down s-antigen in a more effective way than ARC-520. We’ll just have to see if that bears out in humans, and if that’s the case the goal right now is to continue to treat and to bring that s-antigen down as well as x and other antigens to a level where the body can take over. So that’s our plan right now. Could it be that the body needs that jolt, of removing therapy it’s possible but we just don’t know the answer to that at this point and so right now we are just going to – the plan is to dose for it for a certain period of time and see what we see. The second question relating is our call relating to a proof of concept data for HBV and AAT. I don’t think we want to give too much guidance on that at this point just because we don’t know when we are going to start dosing. Once we filed those CPAs we’ll let you know and then once we start dosing patients we will also let you know. Once we are actually dosing patients, I think we can give more granular guidance about when we think that we can start to have data. So I think it’s best for us just to wait until that happens and then we can talk about it. As Bruce mentioned, I think we’ve got really good potential protocols there that would give us early read outs, but we need to ensure that those protocols are approved by regulators and that we can start on at a reasonable time. So we’ll let you know as soon as we know on that. And then the final one with respect to safety, we don’t have anything more to say at this point. We do expect as much wider safety margin with the new TRiM platform than with DPCs. We are in GLP tox talks right now and so once that’s finished we’ll go to the clinic and see where we are, but we certainly do expect a good wide safety margin with that whole platform.

[Operator Instructions] Our next question comes from the line of Elemer Piros with Cantor. Your line is now open.

Good afternoon, gentlemen. I was wondering maybe if you could help me to understand what is it in the new design that makes this version of the RNAi against HBV more efficacious against even integrated DNA.

Thanks, Elemer. Bruce, do you want to walk through where the sequences as here, at least broadly?

Yes, sure. So, Elemer the – this isn’t overlapping transcriptome at the three prime end, but the X protein is quite short. And in ARC-520 both of the RNAi triggers were both targeted in that X region, now that turns out to be the region that’s frequently lost during integration. So, in ARO-HBV one of the triggers is still in that X region, but the other trigger is quite a way it’s upstream in the S region and in that part of the DNA that is almost always preserved during integration. So it’s that second trigger being quite safely out of that X region that gives us confidence that ARO-HBV should also knock down the integrated source of – so in fact we created an animal model to try to test that hypothesis as best as we could and that model gave very good knock down of the s-antigen even when the X trigger was essentially taken out of the picture.

And let me underline one thing Elemer and I know you recognize this, but I want to make sure it’s clear to others who are on the call. So when we developed ARC-520 the world didn’t appreciate the importance of integrated DNA as a source of s-antigen. It just wasn’t clear, you know we discovered that again as you know and so just by rotten luck, we had both of our sequences in ARC-520 that were in a region that is often lost during integration. Now it turns out that was actually fortuitous because it enabled us to understand this whole new biological force within the virus. But the downside of course was that we were only knocking down one part of produced S, and so now ARO-HBV if it works as designed, it is not going to have that floor, right with ARC-520 we can knock down only so much that was quite off in cccDNA but it still left this floor that’s being produced by integrated DNA and now the floor is gone. And so it will be interesting to see how much knock down we are able to get with ARC-HBV. That’s – anyway so I think that is important to understand.

Yes, thank you very much for that. And so Bruce, if you compare the data that you just presented, I thought the mice data, was the data with 520 as impressive as this was?

So first for the wild type DNA model, it was very similar I would say between ARC-520 and ARO-HBV although that’s a model that’s purely indicative of cccDNA. At that time we had not created this new plasmid model to knock out that, our X trigger. So we did not have anything comparable with ARC-520. We didn’t know to build that. So this is – but I think with respect to cccDNA derived transcripts, this would look very similar I would say to what was achieved with ARC-520.

And also keep in mind we are talking about S here and we think S is important, but we know a little bit that the other gene products are important as well and so it’s important to point out that we are not just knocking down S, we are knocking down as we mentioned in our prepared remarks we think everything this virus is producing and one of those important ones is X antigen. Gilead has done some very interesting work that suggests the real importance for X antigen. And so we think that any RNAi therapy that does not knock down X is going to do it at its parallel.

Okay, okay. And Bruce in the long term follow up data that you’ve also presented with 520, I think the RNAi product was given four to seven times or four to nine, monthly infusions. At what point was entecavir stopped? Or was it continuous?

So entecavir was used in these patients. So they started you know a line when they got their first dose of ARC-520 and they are still continuing today entecavir.

Okay, okay. Okay, so that probably didn’t have an impact on triggering those response.

No historically the nukes really do very little for antigenemia. And you know in the -- those rare cases of course where they do get seroclearance, which is extremely rare, then you see the antigenemia fall but for the most part the nukes are well known to not be very helpful especially with respect to surface antigen.

Okay. And just the last question to Ken. Ken, how do you envision the cash burn changing, now that you’re moving back into the clinic with potentially five programs by the end of next year?

So if you look at our history of our cash burn this past year we spent about $56 million excluding CapEx and the year before that it was probably about $10 million additional when we are heavier into the clinic. So if you look at our historical cash burn when we were in the clinic and expect to see some increase there in 2018.

Okay, thank you very much gentlemen.

Okay, thanks very much.

We are not showing any further questions in queue at this time. I’d like to turn the call back to Chris Anzalone for any closing remarks.

Thank you all and happy holidays and we wish you a happy new year and we look forward to seeing you in 2018.

Ladies and gentlemen, thank you for your participation in today’s conference. This concludes the program and you may now disconnect. Everyone have a great day.